E

Exact Sciences Corp
D

EXAS

56.980
USD
0.49
(0.87%)
مغلق
حجم التداول
61,576
الربح لكل سهم
-0
العائد الربحي
-
P/E
-10
حجم السوق
10,748,574,608
أصول ذات صلة
ABBV
ABBV
0.810
(0.44%)
183.260 USD
BAX
BAX
-0.165
(-0.55%)
30.110 USD
BDX
BDX
-0.820
(-0.48%)
171.380 USD
BSX
BSX
0.050
(0.05%)
104.520 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
ILMN
ILMN
-0.160
(-0.20%)
80.380 USD
MDT
MDT
-0.250
(-0.31%)
80.670 USD
M
MYGN
-0.01500
(-0.38%)
3.92000 USD
SYK
SYK
-1.79
(-0.47%)
376.66 USD
T
TNDM
0.080
(0.39%)
20.730 USD
VRTX
VRTX
1.79
(0.41%)
435.79 USD
المزيد
الأخبار المقالات

العنوان: Exact Sciences Corp

القطاع: Healthcare
الصناعة: Diagnostics & Research
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, aliquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.